儿童肿瘤协作组试验中放射治疗技术的演变(1998–2025)
该研究基于儿童肿瘤协作组(COG)1998至2025年含放疗方案的试验元数据,描述不同放疗模态随时间及病种的变化。结果显示三维光子治疗从73%降至15%,IMRT/VMAT从26%升至89%,质子放疗从2%增至2021年近40%后趋稳,所有模态协议依从性>90%。
要点
- 三维光子治疗占比从1998年73%降至2025年15%,IMRT/VMAT从26%升至89%。
- 质子放疗从2000年前2%增至2021年近40%后趋稳,48项试验含质子治疗患者。
- 所有放疗模态的质控审查协议依从性在国内和国际均>90%。
核心结论
- 25年间光子治疗从三维适形转向IMRT/VMAT,质子放疗持续扩展,尤其在中枢神经系统肿瘤及横纹肌肉瘤/软组织肉瘤试验中。
研究设计与样本
- 查询影像与放射肿瘤学核心数据库,纳入1998至2025年至少1例患者接受放疗的83项COG试验,提取方案元数据及患者层面变量进行描述性统计。
主要发现
- 研究人群共8898例患者,其中美国7881例、其他国家1017例,入组中位年龄9岁。
- 83项试验中48项至少含1例接受质子放疗的患者,允许质子放疗的试验数在2010年达峰为17项。
- 中枢神经系统肿瘤及横纹肌肉瘤/软组织肉瘤试验在试验数和入组数上均占主导,且最早纳入质子放疗。
- 1998至2025年,三维光子治疗占比从73%降至15%,IMRT/VMAT从26%升至89%。
- 质子放疗使用率从2000年前2%增至2021年近40%,此后趋于稳定;所有模态协议依从性>90%。
关键数值与推荐
- 三维光子治疗占比从1998年73%降至2025年15%。
- IMRT/VMAT使用率从1998年26%升至2025年89%。
- 质子放疗使用率从2000年前2%增至2021年近40%后趋稳。
- 所有放疗模态的质控审查协议依从性在国内和国际均>90%。
临床怎么用
- 儿童肿瘤放疗中光子技术已从三维适形转向IMRT/VMAT,质子放疗应用持续扩大。
- 中枢神经系统肿瘤及横纹肌肉瘤/软组织肉瘤试验是质子放疗推广的主要病种。
- 高协议依从性支持COG试验放疗质控体系在国内外多中心的可推广性。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Significant advancements in external beam radiation therapy (RT) over the past 20+ years have occurred with evolution from 2-dimensional techniques based on plain film x rays to 3-dimensional conformal and intensity modulated photon techniques. Likewise, proton radiation therapy (PRT) was also introduced and has become more widely available. Each advance in radiation technique improves targeting and has the potential to mitigate late effects associated with RT. In this study, we use metadata from past and present Children's Oncology Group trials that included RT to describe the evolution of different RT modalities across time and disease sites. METHODS AND MATERIALS: Imaging and Radiation Oncology Core database was queried for protocols with at least 1 patient receiving RT from 1998 to 2025. Protocol metadata, including primary disease site, study timeline, and quality assurance , was extracted, as were nonidentifiable patient-level variables including age, institution, year of enrollment, and RT modality used. Descriptive statistics were used for downstream analysis. RESULTS: The study population comprised 8898 patients, including 7881 from the United States and 1017 from other countries. The median age at enrollment was 9 years; California, Texas, Florida, and New York were among the top contributing states. Of the 83 included Children's Oncology Group trials, 48 included at least 1 patient receiving PRT. The number of trials allowing PRT peaked in 2010 with 17 protocols. Trials involving central nervous system tumors and rhabdomyosarcoma/soft tissue sarcomas dominated both in the number of trials and enrollment. They were also among the earliest to incorporate PRT into treatment protocols. From 1998 to 2025, 3-dimensional photon-based treatments declined from 73% to 15%, whereas intensity modulated radiation therapy/volumetric modulated arc therapy usage rose from 26% to 89% over the same interval. The use of PRT increased from 2% pre-2000 to nearly 40% in 2021, which has since stabilized. Quality assurance review demonstrated >90% protocol compliance across all RT modalities both nationally and internationally. CONCLUSIONS: Over 25 years of Children's Oncology Group experience, photon therapy has transitioned from 3-dimensional conformal to intensity modulated radiation therapy/volumetric modulated arc therapy, whereas PRT use has continued to expand, particularly in central nervous system and rhabdomyosarcoma/soft tissue sarcomas trials. These trends highlight how pediatric cooperative group studies continue to shape national standards and underscore the need for future work linking modality adoption with toxicity, survivorship, and access across diverse treatment settings.
引用
- Gallitto M, Zhang H, Iandoli M, et al. The Evolution of Radiation Therapy in Children's Oncology Group Trials, From 1998 to 2025. Int J Radiat Oncol Biol Phys. 2026. PMID: 42603563. doi:10.1016/j.ijrobp.2026.07.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。